Pancreatic ductal adenocarcinoma: Clinical trials to watch.

IF 13.3 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2026-09-11 DOI:10.1016/j.medj.2026.101268

Vincent P Groot, I Quintus Molenaar, Geert A Cirkel, Christopher L Wolfgang, Hjalmar C Van Santvoort

引用次数: 0

Abstract

The treatment of PDAC is transitioning from uniform cytotoxic chemotherapy toward precision strategies guided by molecular identity and disease stage. RAS and PARP inhibitors and personalized neoantigen vaccination have created new options across metastatic and resectable disease. Chemotherapy timing relative to surgery and post-resection surveillance represent other important axes of precision oncology. Seven trials addressing these dimensions may collectively redefine PDAC treatment.

查看原文本刊更多论文

胰腺导管腺癌：值得关注的临床试验。

PDAC的治疗正从统一的细胞毒性化疗向分子特性和疾病分期指导的精确策略过渡。RAS和PARP抑制剂和个体化新抗原疫苗接种为转移性和可切除性疾病创造了新的选择。化疗时间相对于手术和术后监测是精确肿瘤学的另一个重要方面。解决这些方面的七个试验可能共同重新定义PDAC治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.